Merck Profit Tops Wall Street View On Strong Keytruda Sales
Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer immunotherapy drug.
Merck Quarterly Profit Tops Wall Street View On Strong Keytruda Sales
Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer drug Keytruda.
Merck Avoided Billions In U.S. Tax By Offshoring Keytruda Profits - Senator
Drugmaker Merck & Co avoided billions of dollars of U.S.
Revlimid Sales Drive Higher-than-expected Bristol Myers Results
Bristol Myers Squibb Co on Wednesday reported higher-than-expected second-quarter profit as a dropoff in sales of its blockbuster cancer drug Revlimid, which now faces generic competition, was not as steep as projected.
Bristol Myers Profit Beats Estimates On Resilient Revlimid Sales
Bristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared despite competition from generic drugs.
Senate Finance Report Says AbbVie Shifted Profit Overseas To Cut Taxes
Drugmaker AbbVie Inc generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S.
FDA Will Not Require Clinical Trial Data To Authorize Redesigned COVID Boosters -official
The U.S. Food and Drug Administration will not require companies to submit clinical trial data on COVID-19 vaccines modified to protect against the BA.4 and BA.5 Omicron subvariants in order to authorize those shots, a top FDA official said on Thursday.
U.S. FDA To Use Existing Omicron Booster Data To Review Shots Targeting New Subvariants -official
U.S. health regulators will not require companies to submit new clinical trial data on COVID-19 vaccines that target the now dominant BA.4 and BA.5 Omicron subvariants to authorize those shots, but will instead rely on studies showing the efficacy of targeting the earlier BA.1 subvariant, a top official said on Thursday.
Pfizer/BioNTech Say Omicron-based COVID Shots Improve Response Vs That Variant
Pfizer Inc and BioNTech SE said on Saturday that a booster dose of updated versions of their COVID-19 vaccine, modified specifically to combat the Omicron coronavirus variant, generated a higher immune response against that variant.
Analysis-The Next COVID Booster Shots Will Likely Be Updated For Omicron
COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original strain, although some experts suggest they may only offer significant benefits for older and immunocompromised people.
U.S. FDA Staff Says Moderna COVID Vaccine Effective And Safe For Children
U.S. Food and Drug Administration staff reviewers on Friday said Moderna Inc's COVID-19 vaccine appears safe and effective for use in children aged 6 months to 17 years old as a committee of scientists will meet next week to vote on whether to recommend the regulator authorize the vaccine in children.
J&J, AbbVie Cancer Drug Significantly Slows Progression Of Rare Lymphoma: Study
Johnson & Johnson and AbbVie's big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Friday.
Pfizer To Sell All Its Patented Drugs At Nonprofit Price In Low-income Countries
Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.
Pfizer/BioNTech Say 3 COVID Shots Elicit Good Response In Children Under 5
Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
Pfizer/BioNTech Say 3 COVID Shots Generate Good Response In Under-5s
Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under the age of five in their clinical trial.
Explainer-How Concerned Should We Be About Monkeypox?
Global health officials have sounded the alarm over rising cases in Europe and elsewhere of monkeypox, a type of viral infection more common to west and central Africa.
U.S. To Study Whether Longer Paxlovid Course Needed To Combat Reinfections
The U.S. National Institutes of Health is in talks with Pfizer Inc about studying whether a longer course of the drugmaker's COVID-19 antiviral treatment Paxlovid is needed to prevent reinfections, top U.S.
Explainer-Some Patients Reporting COVID Rebounds After Taking Pfizer Pills
More than 2.8 million courses of Pfizer Inc's COVID-19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United States, with the Biden administration working to improve access to the drug.
Bristol Myers 1st-quarter Sales Up On Eliquis, Opdivo
Drugmaker Bristol Myers Squibb posted slightly better-than-expected first-quarter earnings on Friday on growth of sales of its blood thinner Eliquis and cancer drug Opdivo, but said it no longer expects sales growth in 2022 due to stiff generic competition overseas for blood cancer drug Revlimid.
Merck Profit Tops Expectations On Demand For COVID Pill, Cancer Drugs
Merck & Co on Thursday reported quarterly profit and sales that beat estimates and raised its full-year forecasts on strong demand for top-selling cancer drug Keytruda, its Gardasil vaccine and COVID-19 antiviral pill molnupiravir.
Merck Quarterly Profit Tops Expectations On Demand For COVID Pill, Cancer Drugs
Merck & Co posted better-than-expected first-quarter earnings and raised its full-year sales estimate on strength from its top-selling cancer drug Keytruda, human papillomavirus (HPV) vaccine Gardasil and its COVID-19 antiviral pill molnupiravir.
Pfizer To Provide 10 Million Courses Of COVID Pill To Developing Countries -the Global Fund
Pfizer Inc is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries this year, according to an official with the Global Fund, a healthcare NGO working to buy the pills from the drugmaker.
U.S. COVID Vaccine For Children Under 5 Delayed By At Least 2 Months
A U.S. decision on Pfizer and BioNTech's COVID-19 vaccine for infants and children 6 months through 4 years of age has been postponed for at least two months after the Food and Drug Administration (FDA) said it needed more data.
Trump Seeks To Base Medicare Drug Prices On Lower Overseas Rates
President Donald Trump, taking aim at "global freeloading," said Thursday his administration would seek to lower prescription drug prices by basing what the government's Medicare program pays for some medications on the lower prices paid in other countries.
Trump Told Pfizer CEO Price Hikes Hurt His Drug Plan: Source
Donald Trump called Pfizer Chief Executive Ian Read on Tuesday to say the company’s July 1 price hikes had complicated the administration’s drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.